Prudential Financial Inc. boosted its holdings in Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 134.8% in the third quarter, HoldingsChannel reports. The firm owned 112,101 shares of the company’s stock after purchasing an additional 64,360 shares during the quarter. Prudential Financial Inc.’s holdings in Aerie Pharmaceuticals were worth $6,900,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in AERI. Frontier Capital Management Co. LLC bought a new position in Aerie Pharmaceuticals in the second quarter valued at $24,685,000. BlackRock Inc. lifted its stake in Aerie Pharmaceuticals by 9.0% in the second quarter. BlackRock Inc. now owns 2,991,101 shares of the company’s stock valued at $202,049,000 after acquiring an additional 246,686 shares during the last quarter. PointState Capital LP lifted its stake in Aerie Pharmaceuticals by 524.7% in the second quarter. PointState Capital LP now owns 281,600 shares of the company’s stock valued at $19,022,000 after acquiring an additional 236,524 shares during the last quarter. FMR LLC lifted its stake in Aerie Pharmaceuticals by 25.4% in the second quarter. FMR LLC now owns 1,095,652 shares of the company’s stock valued at $74,011,000 after acquiring an additional 221,582 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. lifted its stake in Aerie Pharmaceuticals by 168.5% in the third quarter. Candriam Luxembourg S.C.A. now owns 326,800 shares of the company’s stock valued at $20,115,000 after acquiring an additional 205,100 shares during the last quarter.
Shares of AERI stock opened at $39.69 on Friday. Aerie Pharmaceuticals Inc has a one year low of $38.50 and a one year high of $74.75.
Aerie Pharmaceuticals (NASDAQ:AERI) last posted its earnings results on Tuesday, November 6th. The company reported ($1.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.40). The firm had revenue of $7.30 million for the quarter, compared to the consensus estimate of $5.63 million. Analysts expect that Aerie Pharmaceuticals Inc will post -5.48 EPS for the current fiscal year.
A number of analysts have commented on AERI shares. Stifel Nicolaus increased their price target on shares of Aerie Pharmaceuticals from $80.00 to $87.00 and gave the company a “buy” rating in a research note on Tuesday, September 11th. ValuEngine cut shares of Aerie Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 6th. Cantor Fitzgerald reiterated a “buy” rating and issued a $86.00 price target on shares of Aerie Pharmaceuticals in a research note on Tuesday, October 2nd. Canaccord Genuity reiterated a “buy” rating and issued a $86.00 price target on shares of Aerie Pharmaceuticals in a research note on Friday, August 10th. Finally, JMP Securities set a $80.00 price target on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, October 10th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and eleven have given a buy rating to the company. Aerie Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $79.25.
In other news, insider Casey C. Kopczynski sold 11,000 shares of the firm’s stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $39.81, for a total transaction of $437,910.00. Following the completion of the sale, the insider now owns 118,042 shares in the company, valued at approximately $4,699,252.02. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Richard J. Rubino sold 66,605 shares of the firm’s stock in a transaction dated Thursday, September 27th. The stock was sold at an average price of $60.23, for a total transaction of $4,011,619.15. Following the sale, the chief financial officer now owns 334,236 shares of the company’s stock, valued at approximately $20,131,034.28. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 134,117 shares of company stock valued at $7,784,846. 10.53% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Prudential Financial Inc. Has $6.90 Million Position in Aerie Pharmaceuticals Inc (AERI)” was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.thelincolnianonline.com/2018/12/08/prudential-financial-inc-has-6-90-million-position-in-aerie-pharmaceuticals-inc-aeri.html.
Aerie Pharmaceuticals Profile
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Further Reading: Yield Curve
Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals Inc (NASDAQ:AERI).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.